Immune thrombocytopenia, often known as immune thrombocytopenic purpura (ITP), has
emerged as an important complication of COVID-19. A systematic review was done to …

In February 2022, these guidelines were reviewed by an expert work group convened by
ASH. Review included limited searches for new evidence and discussion of the search …

These guidelines are dedicated to the memory of Dr Clive Kearon of McMaster University in
Hamilton, Ontario, Canada. Dr Kearon extensively reviewed the first and second versions of …

Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy
caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic …

Key Clinical Points Heparin-Induced Thrombocytopenia Heparin-induced thrombocytopenia
(HIT) is characterized by a decrease in the platelet count of more than 50% from the highest …

Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening complication of
heparin exposure. Here, we review the pathogenesis, incidence, diagnosis, and …

Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal,
immunologically mediated adverse drug reaction to unfractionated heparin or, less …

Anticoagulants are potent therapeutics widely used in medical and surgical settings, and the
amount spent on anticoagulation is rising. Although warfarin remains a widely prescribed …

Autoimmune disorders are often associated with low platelet count or thrombocytopenia. In
immune-induced thrombocytopenia (IIT), a common mechanism is increased platelet …

There are currently no effective substitutes for high intensity therapy with unfractionated
heparin (UFH) for cardiovascular procedures based on its rapid onset of action, ease of …